Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 295

Sort by

Sort Order Select

Journal Articles

Single cell analysis of chronic myeloid leukemia bone marrow from time of TKI discontinuation reveals stem cell alterations associated with recurrence versus treatment free remission

Tyler Freeland, Na Xie, Ashley Rennhack, Soo-Hyun Kim, Shanrun Liu, Dong-Wook Kim, Changde Cheng, Ravi Bhatia

Blood (2025) 146 (Supplement 1): 356.

https://doi.org/10.1182/blood-2025-356

Published: 2025

Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Blood (2025) 146 (Supplement 1): 73.

https://doi.org/10.1182/blood-2025-73

Published: 2025

Journal Articles

High-dose ponatinib in Korean CML and Ph+ ALL: real-world outcomes in early and heavily pretreated settings

Dong-Wook Kim, Seok Lee

Blood (2025) 146 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2025-4614

Published: 2025

Journal Articles

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Blood (2025) 146 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2025-1997

Published: 2025

Journal Articles

Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response

Sewon Lee, Yeung-Chul Mun, Hongtae Kim, Sung-Ho Park, Semin Lee, Seunghoon Kim, Sung-Hyun Kim, Young Rok Do, Soo-Hyun Kim, Kyung-Mi Kee, Sahee Park, Dong-Wook Kim

Blood (2025) 146 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2025-2002

Published: 2025

Journal Articles

Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts

Andreas Hochhaus, Susanne Saussele, Valerie Coiteux, Dong-Wook Kim, Yingsi Yang, Qi Wang, Brianna Hoffner, Damiette Smit, Fabian Lang

Blood (2025) 146 (Supplement 1): 3771.

https://doi.org/10.1182/blood-2025-3771

Published: 2025

Journal Articles

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Elias Jabbour, Timothy Hughes, Richard Van Etten, David Andorsky, Gonzalo Carreño, Philipp le Coutre, Omer Jamy, Pilar Giraldo, Dong-Wook Kim, Vivian Oehler, Andreas Hochhaus, Jorge Cortes, Michael Mauro, Tonya Marmon, Leanne Holes, Emil Kuriakose, Hagop Kantarjian, Delphine Rea

Blood (2025) 146 (Supplement 1): 901.

https://doi.org/10.1182/blood-2025-901

Published: 2025

Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Blood (2025) 146 (Supplement 1): 5549.

https://doi.org/10.1182/blood-2025-5549

Published: 2025

Journal Articles

Novel Microfluidic and AI-Based Approach for Personalized Drug Selection in Chronic Myeloid Leukemia (CML) Patients

Hwisu Jeon, Yukyung Park, Eujin Um, Hongtae Kim, Chang-Yeol Jung, Dong-Wook Kim, Taesung Kim

Blood (2024) 144 (Supplement 1): 7482.

https://doi.org/10.1182/blood-2024-199886

Published: 2024

Journal Articles

Novel Chip-Based Digital Real-Time PCR Platform with Lab on an Array for the Sensitive Detection of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia

Hyun-Woo Song, Sung-Hyun Kim, Young Rok Do, Kyung-Mi Ki, Soo Hyun Kim, Min-Sik Song, Seung-Shick Shin, Dong-Wook Kim

Blood (2024) 144 (Supplement 1): 6596.

https://doi.org/10.1182/blood-2024-206252

Published: 2024

Journal Articles

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

Elias Jabbour, Delphine Rea, Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Dong-Wook Kim, Hagop M. Kantarjian, Leanne Holes, Emil T. Kuriakose, Michael J. Mauro

Blood (2024) 144 (Supplement 1): 6594.

https://doi.org/10.1182/blood-2024-204153

Published: 2024

Journal Articles

A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Sewon Lee, Yeung-Chul Mun, Hongtae Kim, Sung-Ho Park, Semin Lee, Seunghoon Kim, Sung-Hyun Kim, Young Rok Do, Soo-Hyun Kim, Kyung-Mi Kee, Yoonsung Lee, Dong-Wook Kim

Blood (2024) 144 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2024-199242

Published: 2024

Journal Articles

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Gabriel Etienne, Naoto Takahashi, Inho Kim, David Andorsky, Ghayas C. Issa, Felice Bombaci, Shruti Kapoor, Rajendra Jinwal, Lillian Yau, Richard Larson

Blood (2024) 144 (Supplement 1): 475.

https://doi.org/10.1182/blood-2024-203757

Published: 2024

Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Blood (2024) 144 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2024-209537

Published: 2024

Journal Articles

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Timothy P Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Torres Cardoso, Jomy Jose, Monali Sura, Jorge Cortes

Blood (2023) 142 (Supplement 1): 866.

https://doi.org/10.1182/blood-2023-182100

Published: 2023

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Novel Orally Available Degrader to Target Lck in T-Cell Acute Lymphoblastic Leukemia

Na-Rae Jeong, Ye Seul Lim, Sun-Mi Yoo, Han Wool KIM, So Hyuk Kim, Ae-Ran Choi, Dong-Wook Kim, Song Hee Lee

Blood (2023) 142 (Supplement 1): 2262.

https://doi.org/10.1182/blood-2023-185778

Published: 2023

Journal Articles

A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia

Ye Seul Lim, Na-Rae Jeong, Sun-Mi Yoo, Han Wool KIM, Song Hee Lee, Dong-Wook Kim

Blood (2023) 142 (Supplement 1): 5012.

https://doi.org/10.1182/blood-2023-180442

Published: 2023

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

KF1601, a Novel Orally Bioavailable Inhibitor of BCR-ABL1 T315I without Inducing Thrombotic Microangiopathy

Sung-Min Ahn, Dong-Wook Kim

Blood (2023) 142 (Supplement 1): 6352.

https://doi.org/10.1182/blood-2023-190891

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Single cell analysis of chronic myeloid leukemia bone marrow from time of TKI discontinuation reveals stem cell alterations associated with recurrence versus treatment free remission

High-dose ponatinib in Korean CML and Ph+ ALL: real-world outcomes in early and heavily pretreated settings

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response

Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Novel Microfluidic and AI-Based Approach for Personalized Drug Selection in Chronic Myeloid Leukemia (CML) Patients

Novel Chip-Based Digital Real-Time PCR Platform with Lab on an Array for the Sensitive Detection of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Novel Orally Available Degrader to Target Lck in T-Cell Acute Lymphoblastic Leukemia

A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia

KF1601, a Novel Orally Bioavailable Inhibitor of BCR-ABL1 T315I without Inducing Thrombotic Microangiopathy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only